All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, February 8, 2023
Home » Authors » Mark McCarty

Mark McCarty

Articles

ARTICLES

FDA icons and doctor

CDS Coalition petitions FDA to rewrite clinical decision support final guidance

Feb. 8, 2023
By Mark McCarty
No Comments
The U.S. FDA raised some hackles with its final guidance for clinical decision support (CDS) software, thanks to provisions that some stakeholders argued flew against congressional intent regarding the regulatory status of some device functions. That final guidance is now the target of a petition by the CDS Coalition to withdraw and rewrite the final guidance, arguing that the agency is “doing an end run” around the limitations established by Congress regarding the FDA’s oversight of software as a medical device (SaMD).
Read More
World map with supply chain icons

FDA, industry team up in effort to improve product quality, supply chain resiliency

Feb. 7, 2023
By Mark McCarty
No Comments
The U.S. FDA and makers of medical devices have several collaborative programs, but the two sides have joined forces yet again in a new collaboration, this time to address both product quality issues and supply chain resiliency. 
Read More

Chief product security officer a key in cybersecurity program maturity

Feb. 7, 2023
By Mark McCarty
No Comments
The Medical Device Innovation Consortium (MDIC) has played a key role in fostering a stronger industrial appreciation for the need for robust cybersecurity, but a recent MDIC report noted that many device makers are deficient in pushing cybersecurity considerations into the domain of design controls. However, the most critical element in cybersecurity may be whether a company has a chief product security officer (CPSO), the presence of absence of which seems to correlate strongly and uniformly with all aspects of cybersecurity in a manufacturer’s products.
Read More

US GAO says HHS lacks funding for pandemic response preparedness plan

Feb. 6, 2023
By Mark McCarty
No Comments
The U.S. Government Accountability Office (GAO) has sounded off again about the ability of other federal government agencies to respond to future crises and pandemics, arguing that the Department of Health and Human Services (HHS) has not forged a comprehensive assessment mechanism to account for the associated medical countermeasure production needs. However, GAO also remarked that HHS does not have a dedicated funding mechanism to finance these activities, a resource that might not become available until after HHS officials draft a budget for the activities associated with such efforts for congressional review.
Read More

US DOJ withdraws 1996 enforcement discretion policy for hospital capital equipment

Feb. 6, 2023
By Mark McCarty
No Comments
The U.S. Department of Justice (DOJ) reported the withdrawal of three legacy enforcement policies related to health care, including a 1996 policy that allowed hospitals to share the cost of capital equipment such as MRI systems. The announcement would seem to jeopardize the ability of smaller hospitals and other health care clinical sites to share the cost of these and other examples of costly, high-end equipment, but the damage may not stop there, thanks to the elimination of policies regarding medical information sharing that could impede medical research.
Read More

MDMA’s Leahey says Medicare breakthrough device coverage still a work in progress

Feb. 3, 2023
By Mark McCarty
No Comments
The Medical Device Manufacturers Association (MDMA) has led the policy charge for smaller medical device manufacturers for decades, but each year brings its own unique set of hazards and opportunities. In an interview with BioWorld, MDMA President and CEO Mark Leahey said that while the Medicare policy for coverage of breakthrough devices has gone through some unanticipated twists and turns, that policy is not yet fixed and thus there is still some prospect that such a policy will not devolve into a stew of leftovers drawn from existing coverage mechanisms.
Read More
Close-up of eye with digital focus

Human factors engineering a requirement for software used with cameras for vital signs

Feb. 2, 2023
By Mark McCarty
No Comments
The U.S. FDA recently posted the regulation for software used to derive vital signs from optical camera images thanks to a successful de novo petition by Oxford, U.K.-based Oxehealth Ltd., a regulation that carries the usual requirements for software verification and validation. However, the regulation also requires some human factors engineering (HFE) studies of the software interface, a requirement that may become more demanding to fulfill per a recent draft guidance on the subject.
Read More

FTC’s energy labeling rule draws fire from MITA over servicing provisions

Feb. 2, 2023
By Mark McCarty
No Comments
The U.S. Federal Trade Commission (FTC) has once again waded into the question of whether medical devices should be included in the agency’s right-to-repair discussion, most recently in an advanced notice of proposed rulemaking ostensibly titled for energy labeling. The Medical Imaging & Technology Alliance (MITA) pushed back on the proposal by pointing to the draft’s required disclosure of proprietary information about a medical device system, a provision MITA said might detract from patient safety.
Read More
Green traffic light

FDA posts regulation in response to Paige.AI’s de novo for prostate scoring system

Feb. 1, 2023
By Mark McCarty
No Comments
New York-based Paige.AI Inc., was successful in its de novo application to the U.S. FDA for the company’s digital pathology software for identification of cancerous prostate tissue, but the agency needed nearly a year and a half after the September 2021 grant of de novo petition to post the regulation for this novel algorithm. 
Read More

FDA hammers Righteye for off-label promotion of visual impairment system

Feb. 1, 2023
By Mark McCarty
No Comments
The U.S. FDA inked a Dec. 20, 2022, warning letter to Righteye LLC that handed the company a list of quality system issues in dire need of redress, but the agency was more concerned about off-label promotion of the Righteye vision system as a method for evaluating the patient’s ocular tremors as a sign of Parkinson’s disease.
Read More
View All Articles by Mark McCarty

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld
    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 8, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Feb. 8, 2022.
  • Setpoint Medical - vagus nerve stimulation device

    Setpoint Medical lands up to $145M to advance RA implant

    BioWorld MedTech
    Bioelectronic medicine startup Setpoint Medical Corp. raised $80 million in a preferred stock financing co-led by new investors Norwest Venture Partners and...
  • Brain with clock hands, day and night background

    12-Hour as well as circadian brain rhythms disrupted in people with schizophrenia

    BioWorld Science
    Research shows that individuals with schizophrenia have abnormal gene expression patterns in their brains compared with people without the condition. In a study...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing